2022-503102-20-00招募中1 期
A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Different Doses of these Medications can be Tolerated by the Body
Zai Lab (Shanghai) Co. Ltd.8 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年8月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Nehal Parikh
Scientific
Zai Biopharmaceutical (Suzhou) Co. Ltd.
研究点 (8)
Loading locations...
相似试验
招募中
2 期
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)2024-515646-16-00AGO Research GmbH42
招募中
2 期
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentNCT07275216City of Hope Medical Center23
招募中
1 期
Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol ALung Cancer2023-509571-16-00Revolution Medicines Inc.158
招募中
2 期
Pembrolizumab in locally advanced sinonasal carcinoma - NeoPeSino2023-505917-25-00Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb28
招募中
3 期
A Study to Evaluate how Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) whose Current Treatment is not Working Efficiently2024-519709-37-00Regeneron Pharmaceuticals Inc.8